Literature DB >> 9001290

Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group.

J D Stansell1, D H Osmond, E Charlebois, L LaVange, J M Wallace, B V Alexander, J Glassroth, P A Kvale, M J Rosen, L B Reichman, J R Turner, P C Hopewell.   

Abstract

The Pulmonary Complications of HIV Infection Study is a prospective, multicenter, observational study evaluating pulmonary disease among HIV-infected persons. For approximately 52 mo, 1,182 HIV-infected subjects were followed. All participants were evaluated for pulmonary disease on a predetermined schedule. There were 145 episodes of Pneumocystis carinii pneumonia (PCP). Low CD4 count correlated with risk of PCP (p < 0.0001); 79% had CD4 counts less than 100/microl and 95% had CD4 counts less than 200/microl. Subtle changes in diffusing capacity for carbon monoxide (DLCO) were associated with PCP. Univariate analysis identified recurrent undiagnosed fevers, night sweats, oropharyngeal thrush, and unintentional weight loss to be associated with risk among persons with CD4 counts above 200/microl. Subjects in whom CD4 counts declined to below 200/microl and who were not receiving preventive therapy were nine times more likely to develop PCP within 6 mo compared with subjects who received such therapy. A strong trend toward differences between the sexes was detected. Black subjects had less than one third the risk of developing PCP as did white subjects (p < 0.0001). There was no significant difference in risk by HIV transmission category, study site, frequency of follow-up, age, education, smoking history, or use of antiretroviral therapy. Multivariable analysis revealed low CD4 lymphocyte count (p < 0.0001), use of prophylaxis (p < 0.0001), racial differences (p < 0.0001), and declining DLCO (p = 0.015) to influence risk. Constitutional signs and symptoms indicate increased risk for PCP among HIV-infected persons with CD4 counts above 200/microl.

Entities:  

Mesh:

Year:  1997        PMID: 9001290     DOI: 10.1164/ajrccm.155.1.9001290

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  24 in total

Review 1.  Prophylaxis of Pneumocystis carinii pneumonia: too much of a good thing?

Authors:  R F Miller
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

2.  Increased host resistance against Pneumocystis carinii pneumonia in gammadelta T-cell-deficient mice: protective role of gamma interferon and CD8(+) T cells.

Authors:  Chad Steele; Mingquan Zheng; Erana Young; Luis Marrero; Judd E Shellito; Jay K Kolls
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

3.  Level of understanding of co-trimoxazole use among HIV infected, recurrent pulmonary tuberculosis suspects at a national referral tuberculosis clinic in Kampala, Uganda: a qualitative analysis.

Authors:  Alphonse Okwera; David K Mafigiri; David Guwatudde; Christopher Whalen; Moses Joloba
Journal:  Afr Health Sci       Date:  2015-03       Impact factor: 0.927

Review 4.  Infections in the immunosuppressed host.

Authors:  M Patricia George; Henry Masur; Karen A Norris; Scott M Palmer; Cornelius J Clancy; John F McDyer
Journal:  Ann Am Thorac Soc       Date:  2014-08

5.  Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of pneumocystis pneumonia.

Authors:  Laura McKinley; Alison J Logar; Florencia McAllister; Mingquan Zheng; Chad Steele; Jay K Kolls
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

6.  Dectin immunoadhesins and pneumocystis pneumonia.

Authors:  David M Ricks; Kong Chen; Mingquan Zheng; Chad Steele; Jay K Kolls
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

7.  Acute hemolysis in a patient with a newly diagnosed glioblastoma.

Authors:  Adrian G Murphy; Stuart A Grossman
Journal:  CNS Oncol       Date:  2016-05-27

8.  Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection.

Authors:  Xiaowen L Rudner; Kyle I Happel; Erana A Young; Judd E Shellito
Journal:  Infect Immun       Date:  2007-04-02       Impact factor: 3.441

Review 9.  Evaluation of respiratory disease.

Authors:  Sofya Tokman; Laurence Huang
Journal:  Clin Chest Med       Date:  2013-04-15       Impact factor: 2.878

10.  Cellular immune response to pulmonary infections in HIV-infected individuals hospitalized with diverse grades of immunosuppression.

Authors:  M J Miguez-Burbano; D Ashkin; A Rodriguez; R Duncan; M Flores; B Acosta; N Quintero; A Pitchenik
Journal:  Epidemiol Infect       Date:  2006-04       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.